Drug Approval | December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Subscribe To Our Newsletter & Stay Updated
